The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-based combination therapies (ACTs)

Not Open Access | Molecular Surveillance of Drug Resistance of Plasmodium falciparum Isolates Imported from Angola in Henan Province, China

September 30, 2019 - 13:26 -- NOT Open Access
Author(s): 
Ruimin Zhou, Chengyun Yang, Suhua Li, Yuling Zhao, Ying Liu, Dan Qian, Hao Wang, Deling Lu, Hongwei Zhang and Fang Huang
Reference: 
Antimicrob. Agents Chemother. September 2019 63:e00552-19

Angola was the main origin country for the imported malaria in Henan Province, China.

Country: 
Medical Condition: 

NOT Open Access | Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies

June 24, 2019 - 16:15 -- NOT Open Access
Author(s): 
Karryn Gresty, Karen Anderson, Cielo Pasay, Norman C. Waters and Qin Cheng
Reference: 
Antimicrob. Agents Chemother. June 2019 63:e00536-19

The South Pacific countries Solomon Islands, Vanuatu, and Papua New Guinea (PNG) adopted artemisinin-based combination therapies (ACTs) in 2008.

NOT Open Access | Photo-Induced Electron Transfer Real-Time PCR for Detection of Plasmodium falciparum plasmepsin 2 Gene Copy Number

August 1, 2018 - 14:37 -- NOT Open Access
Author(s): 
Samaly Santos Souza, Mariangela L'Episcopia, Carlo Severini, Venkatachalam Udhayakumar and Naomi W. Lucchi
Reference: 
Antimicrob. Agents Chemother. August 2018 62:e00317-18

Piperaquine is an important partner drug used in artemisinin-based combination therapies (ACTs).

NOT Open Access | Drug resistance in Plasmodium

February 14, 2018 - 15:55 -- NOT Open Access
Author(s): 
Kasturi Haldar, Souvik Bhattacharjee & Innocent Safeukui
Reference: 
Nature Reviews Microbiology volume 16, pages 156–170 (2018)

A marked decrease in malaria-related deaths worldwide has been attributed to the administration of effective antimalarials against Plasmodium falciparum, in particular, artemisinin-based combination therapies (ACTs).

A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine

July 11, 2017 - 16:25 -- Open Access
Author(s): 
Satish K. Dhingra, Devasha Redhi, David A. Fidock, et al.
Reference: 
mBio vol. 8 no. 3 e00303-17, 9 May 2017

Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia.

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis

January 14, 2017 - 16:25 -- Open Access
Tags: 
Author(s): 
Richard M. Hoglund, Lesley Workman, Joel Tarning, et al.
Reference: 
PLoS Med 14(1): e1002212

The derived population pharmacokinetic model was used to develop a revised dose regimen of dihydroartemisinin-piperaquine that is expected to provide equivalent piperaquine exposures safely in all patients, including in small children with malaria.

NOT Open Access | How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

September 21, 2015 - 17:00 -- NOT Open Access
Tags: 
Author(s): 
Ian M. Hastings, Katherine Kay, and Eva Maria Hodel
Reference: 
Antimicrob. Agents Chemother. October 2015 vol. 59 no. 10 6428-6436

Artemisinin-based combination therapies (ACTs) are currently the first-line drugs for treating uncomplicated falciparum malaria, the most deadly of the human malarias.

Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device

August 5, 2015 - 11:41 -- Open Access
Tags: 
Author(s): 
Katia Bruxvoort, Charles Festo, Matthew Cairns, Admirabilis Kalolella, Frank Mayaya, S. Patrick Kachur, David Schellenberg, Catherine Goodman
Reference: 
PLoS ONE 10(7): e0134275

Smart blister packs resulted in lower estimates of timely completion of AL and may be less prone to recall and social desirability bias.

Randomized Comparison of the Efficacies and Tolerabilities of Three Artemisinin-Based Combination Treatments for Children with Acute Plasmodium falciparum Malaria in the Democratic Republic of the Congo

August 19, 2014 - 14:12 -- Open Access
Author(s): 
M. A. Onyamboko, C. I. Fanello, K. Wongsaen, J. Tarning, P. Y. Cheah, K. A. Tshefu, A. M. Dondorp, F. Nosten, N. J. White, and N. P. J. Day
Reference: 
Antimicrob. Agents Chemother. September 2014 vol. 58 no. 9 5528-5536

An open-label, randomized controlled trial was carried out in 2011–2012 in the Democratic Republic of the Congo to test the efficacy, safety, and tolerability of the artemisinin-based combination treatments dihydroartemisinin-piperaquine, amodiaquine-artesunate, and artemether-lumefantrine.

NOT Open Access | Ex Vivo Responses of Plasmodium falciparum Clinical Isolates to Conventional and New Antimalarial Drugs in Niger

June 15, 2013 - 12:37 -- NOT Open Access
Author(s): 
Mariama Issaka, Adamou Salissou, Ibrahim Arzika, Julia Guillebaud, Abani Maazou, Sabine Specht, Halima Zamanka, and Thierry Fandeur
Reference: 
Antimicrob. Agents Chemother. July 2013 vol. 57 no. 7 3415-3419
MalariaWorld

Little is known about resistance of Plasmodium falciparum to antimalarials in Sahelian countries.

Country: 

Pages

Subscribe to RSS - artemisinin-based combination therapies (ACTs)